1. Prognostic significance of positive circumferential resection margin post neoadjuvant chemotherapy in patients with esophageal or gastro-esophageal junction adenocarcinoma
- Author
-
George Papaxoinis, Wasat Mansoor, Vikki Owen-Holt, Simon Galloway, Jamie Mj. Weaver, Ana Patrao, Bilal Alkhaffaf, and Zoe Kordatou
- Subjects
Male ,medicine.medical_specialty ,animal structures ,Esophageal Neoplasms ,Lymphovascular invasion ,medicine.medical_treatment ,Antineoplastic Agents ,Adenocarcinoma ,030204 cardiovascular system & hematology ,Gastroenterology ,Capecitabine ,03 medical and health sciences ,0302 clinical medicine ,Gastrectomy ,Stomach Neoplasms ,Internal medicine ,medicine ,Humans ,Neoadjuvant therapy ,Aged ,Neoplasm Staging ,Retrospective Studies ,Cisplatin ,Chemotherapy ,integumentary system ,business.industry ,fungi ,Margins of Excision ,food and beverages ,Retrospective cohort study ,General Medicine ,Prognosis ,medicine.disease ,Neoadjuvant Therapy ,Oncology ,030220 oncology & carcinogenesis ,embryonic structures ,Female ,Surgery ,Esophagogastric Junction ,business ,Follow-Up Studies ,medicine.drug ,Epirubicin - Abstract
Background The aim of the present study was to assess the prognosis of patients with esophageal or gastroesophageal junction (E/GEJ) adenocarcinoma extending beyond the muscularis propria layer (≥ypT3) and positive circumferential resection margin (CRM), post neoadjuvant chemotherapy. Methods 177 patients were retrospectively studied. The majority (94.9%) received ECX (epirubicin, cisplatin, capecitabine), and all had clear proximal/distal resection margins. CRM was defined as positive (CRM+) when it was directly infiltrated (infiltrated CRM) or when tumor cells were detected within 1 mm from CRM (close CRM) and as negative (CRM-) when tumor cells were found in a distance > 1 mm from CRM. Results CRM+ was found in 83 patients (46.9%). Of them, infiltrated CRM was recorded in 36 (20.3%) and close CRM in 47 (26.6%). Adjuvant chemotherapy was administered to 132 patients (74.6%). Lymphovascular invasion and primary site in the lower esophagus were independently associated with higher risk of CRM+. Patients with infiltrated CRM, compared to those with close CRM and those CRM-, had the shortest median time-to-relapse (11.4 vs. 15.6 vs. 22.1 months, respectively, p = 0.005) and overall survival (18.7 vs. 23.1 vs. 38.8 months, respectively, p = 0.001). However, CRM status was not an independent predictor of poor outcome. Symptomatic isolated locoregional recurrences were rare in both CRM+ and CRM-patients (4/56 [7.1%] vs. 5/52 [9.6%], p = 0.736), as well as in infiltrated vs. non-infiltrated CRM (CRM- and close CRM) (0/26 [0%] vs. 9/82 [11.0%], p = 0.110). Conclusion Although CRM status is associated with poor outcome, it does not represent an independent prognostic factor. The status of CRM did not significantly influence the pattern of cancer relapse.
- Published
- 2019
- Full Text
- View/download PDF